Humanigen

Humanigen, Inc. is a clinical-stage biopharmaceutical company. engages in the development of cell and gene therapies for the treatment of cancers through novel human granulocyte-macrophage colony-stimulating factor neutralization and gene-knockout platforms. The company was founded by Jeng-Horng Her & Robert F. Balint on March 15, 2000 and is headquartered in Essex County, NJ.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Humanigen is a biopharmaceutical company that uses its biologic capabilities and its proprietary platform technology to develop first-in-class human antibody therapeutics. It focuses on preventing the serious and potentially life-threatening side-effects associated with chimeric antigen receptor T-cell (CAR-T) therapy. Its pipeline includes programs such as Lenzilumab, Ifabotuzumab, and HGen005.

Humanigen Inc (NASDAQ: HGEN) announced that The Lancet Respiratory Medicine published results from its LIVE-AIR Phase 3 trial of lenzilumab in hospitalized COVID-19 patients. The Lancet paper concludes, "LIVE-AIR showed that lenzilumab treatment of hospitalized patients with COVID-19 can improve the likelihood of survival without the need for mechanical ventilation, with a safety profile similar to that of placebo.

After FDA Rejection, Humanigen's COVID-19 Drug Hopeful Sees Some Light Of Good News

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen Announces Conference Call and Webcast to Discuss Lancet Respiratory Medicine Publications and Provide a Corporate Update

Humanigen Announces Conference Call and Webcast to Discuss Lancet Respiratory Medicine Publications and Provide a Corporate Update

BURLINGAME, Calif.--(BUSINESS WIRE)--The Lancet Respiratory Medicine Publishes Peer-Reviewed Paper and Independent Expert Commentary on Positive Phase 3 Lenzilumab Results

The Lancet Respiratory Medicine Publishes Peer-Reviewed Paper and Independent Expert Commentary on Positive Phase 3 Lenzilumab Results

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm' with its lead drug candidate, lenzilumab, today announced three abstracts pertaining to the potential use of lenzilumab in hospitalized COVID-19 patients will be presented at the British Thoracic Society Winter 2021 Meeting taking place Nov. 24-26, 2021. The society counts more than 4,000

Humanigen Announces Abstracts Accepted for the British Thoracic Society Winter Meeting 2021

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,' announced that its presentation time at the Jefferies London Healthcare Conference has been changed. Jefferies London Healthcare Conference Timothy Morris, COO and CFO, will now make a corporate presentation at 9:20am EST on November 17, 2021. A livestream will be accessible via the link

Humanigen Announces Revised Time for Presentation at Jefferies London Healthcare Conference

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen Reports Third Quarter and Nine Months Ending September 30, 2021 Financial Results and Provides Corporate Update

Humanigen Reports Third Quarter and Nine Months Ending September 30, 2021 Financial Results and Provides Corporate Update

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen Announces Clinical Trial Collaboration to Evaluate Lenzilumab in Acute Graft Versus Host Disease

Humanigen Announces Clinical Trial Collaboration to Evaluate Lenzilumab in Acute Graft Versus Host Disease

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen Announces Release of Abstracts at ASH

Humanigen Announces Release of Abstracts at ASH

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,' announced that management will present and participate at multiple investors conferences in November 2021. Details of the conferences are as follows: Credit Suisse 30th Annual Healthcare Conference Cameron Durrant, Chairman & CEO, will provide a corporate presentation at 8:00am EST o

Humanigen Announces Participation and Presentation at Multiple Conferences in November

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), today announced the first patient was dosed with lenzilumab in the Precision Approach to Chronic Myelomonocytic Leukemia (‘PREACH-M') clinical trial being sponsored by the South Australian Health and Medical Research Institute (SAHMRI) and funded by a Medical Research Future Fund grant from the National Health and Medical Research Council of the Australian government to the University of Adelaide. Humanigen is pr

First Patient Dosed in Phase 2 Precision Medicine Study of Lenzilumab in Patients with Chronic Myelomonocytic Leukemia (CMML)

BURLINGAME, Calif.--(BUSINESS WIRE)--European Commission selects Humanigen's lenzilumab as one of the 10 most promising treatments for COVID-19

European Commission Selects Humanigen's Lenzilumab as One of the 10 Most Promising Treatments for COVID-19

BURLINGAME, Calif.--(BUSINESS WIRE)--An abstract showing ifabotuzumab tumor targeting at all known sites in glioblastoma patients with no normal tissue uptake will be presented at EANM‘21

Humanigen announces preparation of Phase 1b study of ifabotuzumab in solid tumors following presentation of Phase 1 study results at EANM‘21

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,' announced today that the Company's Board of Directors (the “Board”) has elected John Hohneker, MD, and Kevin Xie, PhD, to serve as independent directors of the Company, effective October 19, 2021. “We are excited about the depth and breadth of experience John and Kevin will add to our Bo

Humanigen Elects John Hohneker, MD, and Kevin Xie, PhD, to Board of Directors

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm' with its lead drug candidate, lenzilumab, today announced a late-breaking (LB) presentation of results from the Company's randomized, double-blind, placebo-controlled LIVE-AIR Phase 3 study at the CHEST Annual Meeting 2021, which is being hosted by the American College of Chest Physicians® (CHEST) virt

Humanigen Announces Late-Breaking Presentation at the CHEST Annual Meeting Highlighting C-Reactive Protein as a Biomarker for Identifying Patients Most Likely to Benefit from treatment with Lenzilumab

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,' announced that a manuscript describing its budget impact model for the treatment of patients hospitalized with COVID-19 is available on medRxiv (link). These results highlight the value of selecting the right treatment for the right hospitalized patients during this time of unprecedented

Humanigen's Budget Impact Model Demonstrates Lenzilumab's Potential Positive Economic Value in Hospitalized COVID-19 Patients

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,' announced today it has entered into an arrangement with Clinigen Group plc (“Clinigen”) a global pharmaceutical Services and Products company, to implement a Managed Access Program for lenzilumab (“LenzMAP™”). LenzMAP will enable access to lenzilumab on a case-by-case basis for hospitali

Humanigen Signs Contract With Clinigen for Lenzilumab Managed Access Program in Europe

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen Announces Participation and Presentation at Multiple Conferences in October

Humanigen Announces Participation and Presentation at Multiple Conferences in October

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm' with its lead drug candidate, lenzilumab, today announced it has submitted all the planned modules as well as a risk management plan and pediatric investigation plan for the lenzilumab Conditional Marketing Authorization (CMA) in hospitalized COVID-19 patients to the UK's Medicines and Healthcare Produ

Humanigen Submits All Planned Modules for Potential Conditional Marketing Authorization from the UK's MHRA

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen Announces Oral Presentation of Lenzilumab LIVE-AIR Phase 3 Study Results at IDWeek 2021

Humanigen Announces Oral Presentation of Lenzilumab LIVE-AIR Phase 3 Study Results at IDWeek 2021

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen announces EMA has appointed rapporteurs as part of process for planned submission of a Marketing Authorization Application for lenzilumab

Humanigen Announces the European Medicines Agency Has Appointed a Rapporteur and Co-rapporteur as Part of the Process Related to the Planned Submission of a Marketing Authorization Application (MAA) for Lenzilumab

New York, New York--(Newsfile Corp. - September 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Humanigen, Inc. ("Humanigen" or the "Company") (NASDAQ: HGEN). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Humanigen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Humanigen, Inc. - HGEN

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,' announced that management will present and participate at multiple virtual investor conferences in September 2021. Details of the conferences are as follows: Baird Global Healthcare Conference Cameron Durrant, Chairman & CEO, will provide a corporate update at 5:30pm EDT on September

Humanigen Announces Participation and Presentation at Multiple Conferences in September

The Food and Drug Administration turned down Emergency Use Authorization of lenzilumab in treating hospitalized COVID-19 patients.

Why Humanigen Stock Is Sinking Today

JPMorgan has downgraded Humanigen Inc (NASDAQ:HGEN) to Underweight from Neutral and withdrew its price target after the FDA rejected its Emergency Use request for lenzilumab for hospitalized COVID-19 patients.  Related Content:   See Why Humanigen Stock Is Plunging To 52-Week Low.

After FDA Rejection This Biopharma Stock Garners Analyst Downgrades, Price Cuts

Humanigen Inc. (NASDAQ:HGEN) shares are trading sharply lower Thursday after the company announced the FDA declined its EUA request for lenzilumab in hospitalized COVID-19 patients. Humanigen was down 51% to $7.43 at time of publication.

News for Humanigen Stock (HGEN)